Price (delayed)
$80.02
Market cap
$2.25B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.94
Enterprise value
$2.28B
Sema4 is a patient-centered health intelligence company dedicated to advancing healthcare through data-driven insights. Sema4 is transforming healthcare by applying AI and machine learning to multidimensional, longitudinal clinical and genomic ...
Highlights
The gross profit has surged by 116% year-on-year and by 22% since the previous quarter
GeneDx Holdings's EPS has surged by 73% YoY and by 38% QoQ
Key stats
What are the main financial stats of WGS
MarketValuationsEarnings
Shares outstanding
28.07M
Market cap
$2.25B
Enterprise value
$2.28B
Price to earnings (P/E)
N/A
Price to book (P/B)
8.96
Price to sales (P/S)
7.04
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
7.45
Revenue
$305.45M
Gross profit
$194.4M
Operating income
-$23.21M
Net income
-$52.29M
EBIT
-$49.6M
EBITDA
-$27.64M
Free cash flow
-$33.99M
Per shareBalance sheetLiquidity
EPS
-$1.94
EPS diluted
-$1.94
Free cash flow per share
-$1.26
Book value per share
$8.93
Revenue per share
$11.36
TBVPS
$9.7
Total assets
$419.38M
Total liabilities
$174.13M
Debt
$116.17M
Equity
$245.25M
Working capital
$143.15M
Debt to equity
0.47
Current ratio
3.61
Quick ratio
3.26
Net debt/EBITDA
-1.12
MarginsEfficiencyDividend
EBITDA margin
-9.1%
Gross margin
63.6%
Net margin
-17.1%
Operating margin
-7.6%
Return on assets
-13%
Return on equity
-24.6%
Return on invested capital
-22.3%
Return on capital employed
-13.6%
Return on sales
-16.2%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
WGS stock price
How has the GeneDx Holdings stock price performed over time
Intraday
-0.11%
1 week
-13.21%
1 month
-19.17%
1 year
784.2%
YTD
4.11%
QTD
-9.65%
Financial performance
How have GeneDx Holdings's revenue and profit performed over time
Revenue
$305.45M
Gross profit
$194.4M
Operating income
-$23.21M
Net income
-$52.29M
Gross margin
63.6%
Net margin
-17.1%
WGS financials
The gross profit has surged by 116% year-on-year and by 22% since the previous quarter
The operating margin has soared by 91% YoY and by 65% from the previous quarter
The operating income has soared by 87% YoY and by 60% from the previous quarter
WGS's net margin has surged by 80% year-on-year and by 45% since the previous quarter
Growth
What is GeneDx Holdings's growth rate over time
WGS growth chart
Valuation
What is GeneDx Holdings stock price valuation
P/E
N/A
P/B
8.96
P/S
7.04
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
7.45
Price to earnings (P/E)
GeneDx Holdings's EPS has surged by 73% YoY and by 38% QoQ
Price to book (P/B)
The stock's P/B is 91% more than its last 4 quarters average of 4.7
The company's equity rose by 20% QoQ and by 8% YoY
Price to sales (P/S)
The stock's P/S is 85% above its last 4 quarters average of 3.8
WGS's revenue has soared by 51% year-on-year and by 14% since the previous quarter
Efficiency
How efficient is GeneDx Holdings business performance
GeneDx Holdings's return on sales has surged by 82% YoY and by 47% QoQ
The ROIC has soared by 81% YoY and by 41% from the previous quarter
The ROA has soared by 66% year-on-year and by 37% since the previous quarter
The ROE has soared by 61% YoY and by 39% from the previous quarter
Dividends
What is WGS's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for WGS.
Financial health
How did GeneDx Holdings financials performed over time
Assets vs liabilities
WGS's total assets is 141% greater than its total liabilities
WGS's quick ratio has surged by 63% since the previous quarter and by 18% year-on-year
The current ratio has increased by 50% since the previous quarter and by 16% year-on-year
Debt vs equity
WGS's debt is 53% smaller than its equity
The company's equity rose by 20% QoQ and by 8% YoY
The debt to equity has declined by 18% since the previous quarter and by 10% year-on-year
Balance sheet
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified. Data from 
and Sharadar.